{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T01:11:03Z","timestamp":1787879463361,"version":"build-2784847793"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["8233009"],"award-info":[{"award-number":["8233009"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013105","name":"Shanghai Rising-Star Program","doi-asserted-by":"publisher","award":["23QA1408100"],"award-info":[{"award-number":["23QA1408100"]}],"id":[{"id":"10.13039\/501100013105","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017950","name":"Shanghai Municipal Health Commission","doi-asserted-by":"publisher","award":["2022YQ065"],"award-info":[{"award-number":["2022YQ065"]}],"id":[{"id":"10.13039\/100017950","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-08208-9","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T16:57:00Z","timestamp":1778086620000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["PARG inhibition in ATM-deficient prostate cancer: from mechanistic discovery to therapeutic potential"],"prefix":"10.1186","volume":"24","author":[{"given":"Xuan","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyu","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiguo","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihaoyun","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiying","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weidong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixiang","family":"Xin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6674-9570","authenticated-orcid":false,"given":"Shancheng","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,6]]},"reference":[{"issue":"4","key":"8208_CR1","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.cell.2021.01.041","volume":"184","author":"R Cuella-Martin","year":"2021","unstructured":"Cuella-Martin R, Hayward SB, Fan X, Chen X, Huang JW, Taglialatela A, et al. Functional interrogation of DNA damage response variants with base editing screens. Cell. 2021;184(4):1081\u2013e9719.","journal-title":"Cell"},{"issue":"5","key":"8208_CR2","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","volume":"161","author":"D Robinson","year":"2015","unstructured":"Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;161(5):1215\u201328.","journal-title":"Cell"},{"issue":"3","key":"8208_CR3","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1200\/JCO.2014.56.2728","volume":"33","author":"B Kaufman","year":"2015","unstructured":"Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balma\u00f1a J, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1\/2 mutation. J Clin oncology: official J Am Soc Clin Oncol. 2015;33(3):244\u201350.","journal-title":"J Clin oncology: official J Am Soc Clin Oncol"},{"issue":"1","key":"8208_CR4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41573-024-01060-w","volume":"24","author":"Y Drew","year":"2025","unstructured":"Drew Y, Zenke FT, Curtin NJ. DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications. Nat Rev Drug Discovery. 2025;24(1):19\u201339.","journal-title":"Nat Rev Drug Discovery"},{"issue":"1","key":"8208_CR5","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1093\/annonc\/mdt384","volume":"25","author":"JM Lee","year":"2014","unstructured":"Lee JM, Ledermann JA, Kohn EC. PARP Inhibitors for BRCA1\/2 mutation-associated and BRCA-like malignancies. Annals oncology: official J Eur Soc Med Oncol. 2014;25(1):32\u201340.","journal-title":"Annals oncology: official J Eur Soc Med Oncol"},{"issue":"1","key":"8208_CR6","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s13045-022-01360-x","volume":"15","author":"S Li","year":"2022","unstructured":"Li S, Wang L, Wang Y, Zhang C, Hong Z, Han Z. The synthetic lethality of targeting cell cycle checkpoints and PARPs in cancer treatment. J Hematol Oncol. 2022;15(1):147.","journal-title":"J Hematol Oncol"},{"key":"8208_CR7","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1146\/annurev.biochem.73.011303.073723","volume":"73","author":"A Sancar","year":"2004","unstructured":"Sancar A, Lindsey-Boltz LA, Unsal-Ka\u00e7maz K, Linn S. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem. 2004;73:39\u201385.","journal-title":"Annu Rev Biochem"},{"key":"8208_CR8","doi-asserted-by":"crossref","unstructured":"Wang D, Ma J, Botuyan MV, Cui G, Yan Y, Ding D, et al. ATM-phosphorylated SPOP contributes to 53BP1 exclusion from chromatin during DNA replication. Sci Adv. 2021;7(25).","DOI":"10.1126\/sciadv.abd9208"},{"issue":"1","key":"8208_CR9","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1146\/annurev-biochem-072324-031915","volume":"94","author":"LA Yates","year":"2025","unstructured":"Yates LA, Zhang X, Burgers PM. DNA Damage and Replication Stress Checkpoints. Annu Rev Biochem. 2025;94(1):195\u2013221.","journal-title":"Annu Rev Biochem"},{"key":"8208_CR10","doi-asserted-by":"publisher","first-page":"103269","DOI":"10.1016\/j.redox.2024.103269","volume":"75","author":"JH Lee","year":"2024","unstructured":"Lee JH. Oxidative stress and the multifaceted roles of ATM in maintaining cellular redox homeostasis. Redox Biol. 2024;75:103269.","journal-title":"Redox Biol"},{"key":"8208_CR11","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.jare.2024.12.023","volume":"74","author":"Y Xie","year":"2025","unstructured":"Xie Y, Liu Y, Lin M, Li Z, Shen Z, Yin S, et al. Targeting ATM enhances radiation sensitivity of colorectal cancer by potentiating radiation-induced cell death and antitumor immunity. J Adv Res. 2025;74:513\u201330.","journal-title":"J Adv Res"},{"issue":"7","key":"8208_CR12","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1038\/s41422-018-0048-0","volume":"28","author":"Z Li","year":"2018","unstructured":"Li Z, Li Y, Tang M, Peng B, Lu X, Yang Q, et al. Destabilization of linker histone H1.2 is essential for ATM activation and DNA damage repair. Cell Res. 2018;28(7):756\u201370.","journal-title":"Cell Res"},{"issue":"21","key":"8208_CR13","doi-asserted-by":"publisher","first-page":"4475","DOI":"10.1016\/j.cell.2023.08.030","volume":"186","author":"MJ Suskiewicz","year":"2023","unstructured":"Suskiewicz MJ, Prokhorova E, Rack JGM, Ahel I. ADP-ribosylation from molecular mechanisms to therapeutic implications. Cell. 2023;186(21):4475\u201395.","journal-title":"Cell"},{"issue":"12","key":"8208_CR14","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1016\/j.molcel.2022.02.021","volume":"82","author":"D Huang","year":"2022","unstructured":"Huang D, Kraus WL. The expanding universe of PARP1-mediated molecular and therapeutic mechanisms. Mol Cell. 2022;82(12):2315\u201334.","journal-title":"Mol Cell"},{"issue":"4","key":"8208_CR15","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/j.cell.2020.09.055","volume":"183","author":"JJ Bonfiglio","year":"2020","unstructured":"Bonfiglio JJ, Leidecker O, Dauben H, Longarini EJ, Colby T, San Segundo-Acosta P, et al. An HPF1\/PARP1-Based Chemical Biology Strategy for Exploring ADP-Ribosylation. Cell. 2020;183(4):1086\u2013e10223.","journal-title":"Cell"},{"issue":"7800","key":"8208_CR16","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1038\/s41586-020-2013-6","volume":"579","author":"MJ Suskiewicz","year":"2020","unstructured":"Suskiewicz MJ, Zobel F, Ogden TEH, Fontana P, Ariza A, Yang JC, et al. HPF1 completes the PARP active site for DNA damage-induced ADP-ribosylation. Nature. 2020;579(7800):598\u2013602.","journal-title":"Nature"},{"issue":"4","key":"8208_CR17","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1136\/gutjnl-2019-319970","volume":"70","author":"J Gout","year":"2021","unstructured":"Gout J, Perkhofer L, Morawe M, Arnold F, Ihle M, Biber S, et al. Synergistic targeting and resistance to PARP inhibition in DNA damage repair-deficient pancreatic cancer. Gut. 2021;70(4):743\u201360.","journal-title":"Gut"},{"key":"8208_CR18","doi-asserted-by":"crossref","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. Cancer J Clin. 2025;75(1):10\u201345.","DOI":"10.3322\/caac.21871"},{"key":"8208_CR19","doi-asserted-by":"publisher","first-page":"100962","DOI":"10.1016\/j.drup.2023.100962","volume":"68","author":"M Cai","year":"2023","unstructured":"Cai M, Song XL, Li XA, Chen M, Guo J, Yang DH, et al. Current therapy and drug resistance in metastatic castration-resistant prostate cancer. Drug Resist updates: reviews commentaries Antimicrob anticancer Chemother. 2023;68:100962.","journal-title":"Drug Resist updates: reviews commentaries Antimicrob anticancer Chemother"},{"issue":"18","key":"8208_CR20","doi-asserted-by":"publisher","first-page":"4869","DOI":"10.1158\/1078-0432.CCR-20-0764","volume":"26","author":"H Kaur","year":"2020","unstructured":"Kaur H, Salles DC, Murali S, Hicks JL, Nguyen M, Pritchard CC, et al. Genomic and Clinicopathologic Characterization of ATM-deficient Prostate Cancer. Clin cancer research: official J Am Association Cancer Res. 2020;26(18):4869\u201381.","journal-title":"Clin cancer research: official J Am Association Cancer Res"},{"issue":"2","key":"8208_CR21","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.euo.2019.12.003","volume":"3","author":"Y Wu","year":"2020","unstructured":"Wu Y, Yu H, Li S, Wiley K, Zheng SL, LaDuca H, et al. Rare Germline Pathogenic Mutations of DNA Repair Genes Are Most Strongly Associated with Grade Group 5 Prostate Cancer. Eur Urol Oncol. 2020;3(2):224\u201330.","journal-title":"Eur Urol Oncol"},{"issue":"6096","key":"8208_CR22","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1126\/science.1225829","volume":"337","author":"M Jinek","year":"2012","unstructured":"Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Sci (New York NY). 2012;337(6096):816\u201321.","journal-title":"Sci (New York NY)"},{"issue":"23","key":"8208_CR23","doi-asserted-by":"publisher","first-page":"3861","DOI":"10.1158\/0008-5472.CAN-23-0816","volume":"83","author":"I de Bruijn","year":"2023","unstructured":"de Bruijn I, Kundra R, Mastrogiacomo B, Tran TN, Sikina L, Mazor T, et al. Analysis and Visualization of Longitudinal Genomic and Clinical Data from the AACR Project GENIE Biopharma Collaborative in cBioPortal. Cancer Res. 2023;83(23):3861\u20137.","journal-title":"Cancer Res"},{"issue":"1","key":"8208_CR24","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s13046-022-02420-3","volume":"41","author":"BK Kim","year":"2022","unstructured":"Kim BK, Kim DM, Park H, Kim SK, Hwang MA, Lee J, et al. Synaptotagmin 11 scaffolds MKK7-JNK signaling process to promote stem-like molecular subtype gastric cancer oncogenesis. J experimental Clin cancer research: CR. 2022;41(1):212.","journal-title":"J experimental Clin cancer research: CR"},{"issue":"Pt 3","key":"8208_CR25","doi-asserted-by":"publisher","first-page":"136486","DOI":"10.1016\/j.chemosphere.2022.136486","volume":"308","author":"X Zhou","year":"2022","unstructured":"Zhou X, Song L, Cong R, Luan J, Zhou X, Wang Y, et al. A comprehensive analysis on the relationship between BDE-209 exposure and erectile dysfunction. Chemosphere. 2022;308(Pt 3):136486.","journal-title":"Chemosphere"},{"issue":"1","key":"8208_CR26","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1038\/s41467-020-16096-w","volume":"11","author":"T Thakar","year":"2020","unstructured":"Thakar T, Leung W, Nicolae CM, Clements KE, Shen B, Bielinsky AK, et al. Ubiquitinated-PCNA protects replication forks from DNA2-mediated degradation by regulating Okazaki fragment maturation and chromatin assembly. Nat Commun. 2020;11(1):2147.","journal-title":"Nat Commun"},{"issue":"1","key":"8208_CR27","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s12943-022-01581-1","volume":"21","author":"J Chou","year":"2022","unstructured":"Chou J, Kaller M, Jaeckel S, Rokavec M, Hermeking H. AP4 suppresses DNA damage, chromosomal instability and senescence via inducing MDC1\/Mediator of DNA damage Checkpoint 1 and repressing MIR22HG\/miR-22-3p. Mol Cancer. 2022;21(1):120.","journal-title":"Mol Cancer"},{"issue":"11","key":"8208_CR28","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1038\/nprot.2013.143","volume":"8","author":"FA Ran","year":"2013","unstructured":"Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. Genome engineering using the CRISPR-Cas9 system. Nat Protoc. 2013;8(11):2281\u2013308.","journal-title":"Nat Protoc"},{"issue":"6","key":"8208_CR29","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/j.molcel.2019.04.003","volume":"74","author":"S Li","year":"2019","unstructured":"Li S, Lavagnino Z, Lemacon D, Kong L, Ustione A, Ng X, et al. Ca(2+)-Stimulated AMPK-Dependent Phosphorylation of Exo1 Protects Stressed Replication Forks from Aberrant Resection. Mol Cell. 2019;74(6):1123\u2013e376.","journal-title":"Mol Cell"},{"issue":"4","key":"8208_CR30","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1038\/sj.bjc.6604903","volume":"100","author":"R Alonzi","year":"2009","unstructured":"Alonzi R, Padhani AR, Maxwell RJ, Taylor NJ, Stirling JJ, Wilson JI, et al. Carbogen breathing increases prostate cancer oxygenation: a translational MRI study in murine xenografts and humans. Br J Cancer. 2009;100(4):644\u20138.","journal-title":"Br J Cancer"},{"issue":"4","key":"8208_CR31","doi-asserted-by":"publisher","first-page":"eaav4340","DOI":"10.1126\/sciadv.aav4340","volume":"5","author":"SH Chen","year":"2019","unstructured":"Chen SH, Yu X. Targeting dePARylation selectively suppresses DNA repair-defective and PARP inhibitor-resistant malignancies. Sci Adv. 2019;5(4):eaav4340.","journal-title":"Sci Adv"},{"issue":"1","key":"8208_CR32","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.jhep.2022.01.026","volume":"77","author":"M Yu","year":"2022","unstructured":"Yu M, Chen Z, Zhou Q, Zhang B, Huang J, Jin L, et al. PARG inhibition limits HCC progression and potentiates the efficacy of immune checkpoint therapy. J Hepatol. 2022;77(1):140\u201351.","journal-title":"J Hepatol"},{"issue":"8","key":"8208_CR33","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1158\/2159-8290.CD-12-0460","volume":"3","author":"CJ Logothetis","year":"2013","unstructured":"Logothetis CJ, Gallick GE, Maity SN, Kim J, Aparicio A, Efstathiou E, et al. Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer. Cancer Discov. 2013;3(8):849\u201361.","journal-title":"Cancer Discov"},{"issue":"10013","key":"8208_CR34","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/S0140-6736(14)61947-4","volume":"387","author":"G Attard","year":"2016","unstructured":"Attard G, Parker C, Eeles RA, Schr\u00f6der F, Tomlins SA, Tannock I, et al. Prostate cancer. Lancet (London England). 2016;387(10013):70\u201382.","journal-title":"Lancet (London England)"},{"issue":"4","key":"8208_CR35","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/nm.4053","volume":"22","author":"A Kumar","year":"2016","unstructured":"Kumar A, Coleman I, Morrissey C, Zhang X, True LD, Gulati R, et al. Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer. Nat Med. 2016;22(4):369\u201378.","journal-title":"Nat Med"},{"issue":"5","key":"8208_CR36","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1056\/NEJMoa1603144","volume":"375","author":"CC Pritchard","year":"2016","unstructured":"Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, et al. Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. N Engl J Med. 2016;375(5):443\u201353.","journal-title":"N Engl J Med"},{"issue":"9","key":"8208_CR37","doi-asserted-by":"publisher","first-page":"Of3","DOI":"10.1158\/2159-8290.CD-NB2016-094","volume":"6","author":"Repair-Gene Mutations","year":"2016","unstructured":"Repair-Gene Mutations. Uncovered in Metastatic Prostate Cancer. Cancer Discov. 2016;6(9):Of3.","journal-title":"Cancer Discov"},{"issue":"11","key":"8208_CR38","doi-asserted-by":"publisher","first-page":"3040","DOI":"10.1158\/0008-5472.CAN-16-3398","volume":"77","author":"A Schmitt","year":"2017","unstructured":"Schmitt A, Knittel G, Welcker D, Yang TP, George J, Nowak M, et al. ATM Deficiency Is Associated with Sensitivity to PARP1- and ATR Inhibitors in Lung Adenocarcinoma. Cancer Res. 2017;77(11):3040\u201356.","journal-title":"Cancer Res"},{"issue":"6","key":"8208_CR39","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1093\/annonc\/mdg240","volume":"14","author":"A Fedier","year":"2003","unstructured":"Fedier A, Schlamminger M, Schwarz VA, Haller U, Howell SB, Fink D. Loss of atm sensitises p53-deficient cells to topoisomerase poisons and antimetabolites. Annals oncology: official J Eur Soc Med Oncol. 2003;14(6):938\u201345.","journal-title":"Annals oncology: official J Eur Soc Med Oncol"},{"issue":"2","key":"8208_CR40","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.eururo.2018.01.035","volume":"74","author":"ES Antonarakis","year":"2018","unstructured":"Antonarakis ES, Lu C, Luber B, Liang C, Wang H, Chen Y, et al. Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide. Eur Urol. 2018;74(2):218\u201325.","journal-title":"Eur Urol"},{"issue":"7612","key":"8208_CR41","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/nature18325","volume":"535","author":"A Ray Chaudhuri","year":"2016","unstructured":"Ray Chaudhuri A, Callen E, Ding X, Gogola E, Duarte AA, Lee JE, et al. Replication fork stability confers chemoresistance in BRCA-deficient cells. Nature. 2016;535(7612):382\u20137.","journal-title":"Nature"},{"issue":"2","key":"8208_CR42","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.molcel.2017.09.036","volume":"68","author":"A Taglialatela","year":"2017","unstructured":"Taglialatela A, Alvarez S, Leuzzi G, Sannino V, Ranjha L, Huang JW, et al. Restoration of Replication Fork Stability in BRCA1- and BRCA2-Deficient Cells by Inactivation of SNF2-Family Fork Remodelers. Mol Cell. 2017;68(2):414\u2013. \u2013\u200930.e8.","journal-title":"Mol Cell"},{"issue":"1","key":"8208_CR43","doi-asserted-by":"publisher","first-page":"5654","DOI":"10.1038\/s41467-019-13508-4","volume":"10","author":"JH Houl","year":"2019","unstructured":"Houl JH, Ye Z, Brosey CA, Balapiti-Modarage LPF, Namjoshi S, Bacolla A, et al. Selective small molecule PARG inhibitor causes replication fork stalling and cancer cell death. Nat Commun. 2019;10(1):5654.","journal-title":"Nat Commun"},{"issue":"47","key":"8208_CR44","doi-asserted-by":"publisher","first-page":"e2413954121","DOI":"10.1073\/pnas.2413954121","volume":"121","author":"R Ravindranathan","year":"2024","unstructured":"Ravindranathan R, Somuncu O, da Costa A, Mukkavalli S, Lamarre BP, Nguyen H, et al. PARG inhibitor sensitivity correlates with accumulation of single-stranded DNA gaps in preclinical models of ovarian cancer. Proc Natl Acad Sci USA. 2024;121(47):e2413954121.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"8208_CR45","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/nrm3737","volume":"15","author":"T Vanden Berghe","year":"2014","unstructured":"Vanden Berghe T, Linkermann A, Jouan-Lanhouet S, Walczak H, Vandenabeele P. Regulated necrosis: the expanding network of non-apoptotic cell death pathways. Nat Rev Mol Cell Biol. 2014;15(2):135\u201347.","journal-title":"Nat Rev Mol Cell Biol"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-08208-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08208-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08208-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T20:03:37Z","timestamp":1778184217000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-08208-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,6]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8208"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-08208-9","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,6]]},"assertion":[{"value":"15 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experimentation proceeds according to the Standard of IACUC (Institutional Animal Care and Use Committee) and performs in according to an established protocol approved by the Ethic Committee of Changzheng Hospital. Ethics approval was obtained by the Institutional Ethics Committee of the Shanghai Changzheng Hospital Hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"All authors have read and approved the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no conflicts of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"648"}}